compounds with anticonvulsant activity are disclosed in Mallikarjuna *et al. J Zhejian Univ Sci B* 2007 *8(7)*, 526-532. A number of 1,2,4-triazine compounds with antiviral activity are disclosed in Davidson *et al. Journal of Pharmaceutical Sciences 67(5)*, 1978, 737-739. A number of 1,2,4-triazine compounds are disclosed in Eid *et al.*, Indian Journal of Chemistry, Section B 1990 *29B(5)* 435-439, Zou *et al., Chinese Journal of Chemistry* 1998 *16(1)*, 58-64, Lu *et al., Youji Huaxue* 1992 *12(6)*, 605-607, Lu *et al., Organic Preparations and Procedures International* 1992 *24(3)*, 358-362 and Konno *et al. Heterocycles 19(10)*, 1982, 1865-8. There is no suggestion or disclosure that any of the above compounds might be useful as A_1 or, particularly, A_{2a} receptor antagonists.

We have now discovered, surprisingly, that certain 1,2,4-triazine compounds bearing certain substituents are useful as A_1 and, particularly, A_{2a} receptor antagonists.

Thus, according to one embodiment~~the first aspect~~ of the disclosure~~invention~~, there is provided a compound of formula I for use in the treatment of a condition or disorder ameliorated by the inhibition of the A_1 or, particularly, the A_{2a} receptor, wherein the compound of formula I has the structure



I

wherein:

R^1 represents H or C_{1-6} alkyl, which latter group may be optionally substituted by one or more of halo, OR^{2a} or $NR^{2b}R^{2c}$;

L^1 and L^2 independently represent CH=CH, a direct bond, O, NR^{3a}, $S(O)_p$, CH_2 or C(O);

R^{2a}, R^{2b}, R^{2c} and R^{3a} independently represent H or C_{1-6} alkyl, which latter group is optionally substituted by one or more halo atoms;

A represents Cy^1 or Het^A;

In one aspect, there is provided a compound of formula Iyd,



Iyd

wherein:

B represents a Cy^{BB} or Het^{BB};

Cy^{BB} represents phenyl optionally substituted by one or more R^{4c} substituents;

Het^{BB} represents a 6-membered aromatic heterocyclic group which contains one or more N atoms, and which Het^{BB} group is optionally substituted by one or more R^{4d} substituents;

R^{4b}, $R^{4b'}$, R^{4c} and R^{4d} represent, independently at each occurrence,

(a) halo,

(b) CN,

(c) C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{5a}, $S(O)_qR^{5b}$, $S(O)_2N(R^{5c})(R^{5d})$, $N(R^{5e})S(O)_2R^{5f}$, $N(R^{5g})(R^{5h})$, B^1-$C(G^1)$-B^2-R^{5i}, aryl and Het^1,

(d) Cy^3, which Cy^3 group is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{6a}, $S(O)_qR^{6b}$, $S(O)_2N(R^{6c})(R^{6d})$, $N(R^{6e})S(O)_2R^{6f}$, $N(R^{6g})(R^{6h})$, B^3-$C(G^1)$-B^4-R^{6i}, aryl and Het^2,

(e) Het^a, which Het^a group is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{7a}, $S(O)_qR^{7b}$, $S(O)_2N(R^{7c})(R^{7d})$, $N(R^{7e})S(O)_2R^{7f}$, $N(R^{7g})(R^{7h})$, B^5-$C(G^1)$-B^6-R^{7i}, aryl and Het^3,

(f) OR^8,

(g) $S(O)_rR^{9a}$,

(h) $S(O)_2N(R^{9b})(R^{9c})$,

(i) $N(R^{9d})S(O)_2R^{9e}$,

(j) $N(R^{9f})(R^{9g})$,

(k) B^7-$C(G^1)$-B^8-R^{9h},

(l) =O,

(m) =S,

rr2 represents 0 to 2;

ss and tt independently represent, at each occurrence 0 or 1, provided that ss and tt do not both represent 0;

L^1 and L^2 both represent direct bonds;

G^1 represents, independently at each occurrence, O, S or NR^{5j};

R^8 represents, independently at each occurrence,

H,

Cy^3, Het^a, $aryl^a$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-8} cycloalkyl, which latter seven groups are optionally substituted by one or more substituents selected from halo, -CN, C_{3-6} cycloalkyl, aryl, Het^4, $-C(O)OR^{10}$, $-C(O)R^{11}$, $-C(O)N(R^{N1})(R^{N2})$, $S(O)_rR^{9aa}$, $S(O)_2N(R^{9ba})(R^{9ca})$, $N(R^{9da})S(O)_2R^{9ea}$ and $N(R^{9fa})(R^{9ga})$;

Cy^3 represents, independently at each occurrence, a 3- to 6-membered aromatic, fully saturated or partially unsaturated carbocyclic ring;

Het^a represents, independently at each occurrence, a 3- to 6-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N;

R^{10} and R^{11} independently represent

(a) H,

(b) C_{1-6} alkyl optionally substituted by one or more substituents selected from halo, aryl, $-N(R^{N3})(R^{N4})$ and $-OR^a$,

(c) aryl or

(d) C_{3-7} cycloalkyl (which group is optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

B^1 to B^8 independently represent, at each occurrence, a direct bond, O, S or $N(R^{N3})$;

each $aryl^a$ independently represents a C_{6-14} carbocyclic aromatic group, which group may comprise one, two or three rings;

each aryl independently represents a C_{6-14} carbocyclic aromatic group, which group may comprise one, two or three rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N4})(R^{N5})$ and $-OR^a$, and

$-OR^a$;

Het^1 to Het^4 independently represent 4- to 14-membered heterocyclic groups containing one or more heteroatoms selected from O, S and N, which heterocyclic groups may comprise one, two or three rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N6})(R^{N7})$ and $-OR^a$, and

$-OR^a$;

R^{N1} to R^{N7} independently represent

H,

C_{1-6} alkyl or C_{3-6} cycloalkyl, which latter two groups are optionally substituted by one or more substituents selected from halo and $-OR^a$;

R^a represents, independently at each occurrence,

(a) H;

(b) C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{3-12} cycloalkyl, C_{4-12} cycloalkenyl, which latter five groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl (which latter four groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{12a}, $S(O)_qR^{12b}$, $S(O)_2N(R^{12c})(R^{12d})$, $N(R^{12e})S(O)_2R^{12f}$, $N(R^{12g})(R^{12h})$, B^9-$C(G^2)$-B^{10}-R^{12i}, aryl[1] and Het^b, and which C_{3-12} cycloalkyl or C_{4-12} cycloalkenyl groups may additionally be substituted by =O,

(c) $S(O)_rR^{13a}$,

(d) $S(O)_2N(R^{13b})(R^{13c})$ or

(e) $C(O)$-B^{11}-R^{13d};

R^{5a} to R^{5j}, R^{6a} to R^{6i}, R^{7a} to R^{7i}, R^{9a} to R^{9h}, R^{9aa} to R^{9ga}, R^{12a} to R^{12i} and R^{13a} to R^{13d} independently represent, at each occurrence,

(a) H,

(b) C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{5aa}, $S(O)_qR^{5ab}$, $S(O)_2N(R^{5ac})(R^{5ad})$, $N(R^{5ae})S(O)_2R^{5af}$, $N(R^{5ag})(R^{5ah})$, B^{12}-$C(G^2)$-B^{13}-R^{5ai}, aryl[1] and Het^c;

(c) C_{3-10} cycloalkyl, or C_{4-10} cycloalkenyl (which latter two groups are optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-6} alkyl and C_{1-6} alkoxy),

(d) Het^d;

G^2 represents, independently at each occurence, O, S, or NR^{5aj};

R^{5aa} to R^{5aj} independently represent at each occurrence,

(a) H,

(b) C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy),

(c) C_{3-6} cycloalkyl, or C_{4-6} cycloalkenyl (which latter two groups are optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-4} alkyl and C_{1-4} alkoxy),

(d) Het^e,

or R^{5ag} and R^{5ah} may represent, together with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which may additionally contain one or more heteroatoms selected from O, S and N, which heterocyclic ring is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

B^9 to B^{13} independently represent a direct bond, O, S or $N(R^{N8})$;

$aryl^1$ represents, independently at each occurrence, a C_{6-10} carbocyclic aromatic group, which group may comprise one or two rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N10})(R^{N11})$ and C_{1-6} alkoxy (which latter substituent is optionally substituted by one or more halo atoms), and

C_{1-6} alkoxy (which latter substituent is optionally substituted by one or more halo atoms);

R^{N8}, R^{N10} and R^{N11} independently represent

H,

C_{1-6} alkyl or C_{3-6} cycloalkyl, which latter two groups are optionally substituted by one or more halo atoms;

Het^b represents a 5- or 6-membered that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may be substituted by one or more substituents selected from halo, =O and C_{1-6} alkyl;

Het^c to Het^e independently represent, a 3- to 6-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N, which Het^c to Het^e groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

q and r independently represent at each occurrence 0, 1 or 2; and
unless otherwise specified alkyl, alkenyl, alkynyl, cycloalkyl and the alkyl part of alkoxy groups may be substituted by one or more halo atoms;

or a pharmaceutically acceptable salt or solvate thereof.

In another aspect, there is provided a compound selected from the group comprising:
6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine and
6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine,
or a pharmaceutically acceptable salt or solvate thereof.

In another aspect, there is provided a compound of formula Iyd as defined above for use in the treatment of a condition or disorder ameliorated by the inhibition of the A_1 receptor or the A_{2a} receptor wherein the condition or disorder is selected from: heart failure; kidney failure; oedema; cancer; diabetes; diarrhea; macular degeneration; depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour.

In another aspect, there is provided the use of a compound of formula Iyd as defined above for the manufacture of a medicament for the treatment of a condition or disorder ameliorated by the inhibition of the A_1 receptor or the A_{2a} receptorwherein the condition or disorder is selected from: heart failure; kidney failure; oedema; cancer; diabetes; diarrhea; macular degeneration; depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour.

In another aspect, there is provided a compound of formula Iyd as defined above for use in mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

In another aspect, there is provided the use of compound of formula Iyd as defined above for the manufacture of a medicament for mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

In another aspect, there is provided a compound of formula Iyd as defined above for use in medicine.

In another aspect, there is provided a pharmaceutical formulation including a compound of formula Iyd as defined above in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

In another aspect, there is provided a process for the preparation of a compound of formula Iyd as defined above, which process comprises:

(i)(a) reaction of a compound of formula III,



III

wherein L^{x1a} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, wherein each R^{x1} mentioned herein independently represents a C_{1-6} alkyl group, or, in the case of $-B(OR^{x1})_2$, the two R^{x1} groups may be linked together to form a 4- to 6-membered cyclic group, L^2 represents a direct bond, R^1 represents H, and B is as defined above, with a compound of formula IV,

$$A—X^{1a} \qquad IV$$

wherein X^{1a} represents a suitable leaving group, and A represents the requisite substituted pyridine-4-yl group as defined above;

(b) reaction of a compound of formula V,



V

wherein X^{1b} represents a suitable leaving group, L^2 represents a direct bond, R^1 represents H, and B is as defined above, with a compound of formula VI,

$$A—L^{x1b} \qquad VI$$

wherein L^{x1b} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, wherein each R^{x1} is as defined above, and A represents the requisite substituted pyridine-4-yl group as defined above;

(ii)(a) reaction of a compound of formula XV,



XV

wherein L^{x3a} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, in which each R^{x1} is as defined above, L^1 represents a direct bond, R^1 represents H, and A represents the requisite substituted pyridine-4-yl group as defined above, with a compound of formula XVI,

$$B—X^{3a} \qquad XVI$$

wherein X^{3a} represents a suitable leaving group and B is as defined above;

(b) reaction of a compound of formula XVII,



XVII

wherein X^{3b} represents a suitable leaving group, L^1 represents a direct bond, R^1 represents H, and A represents the requisite substituted pyridine-4-yl group as defined above, with a compound of formula XVIII,

$$B—L^{x3b} \qquad XVIII$$

wherein L^{x3b} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, in which each R^{x1} is as defined above, and B is as defined above;

(iii) reaction of a compound of formula XXVIII,



XXVIII

wherein X^6 represents a suitable leaving group such, L^1 and L^2 represent direct bonds, A represents the requisite substituted pyridine-4-yl group as defined above, and B is as defined above, with a compound of formula XXIX,

R^1NH_2 XXIX

wherein R^1 is H;

(iv) reaction of a compound of formula XXX,



XXX

wherein R^{x2} represents a suitable leaving group, L^1 and L^2 represent direct bonds, A represents the requisite substituted pyridine-4-yl group as defined above, and B is as defined above, or a protected derivative thereof, with a compound of formula XXIX,
wherein R^1 is H;

(v) reaction of a compound of formula XXXI,



XXXI

wherein A represents the requisite substituted pyridine-4-yl group as defined above, and B is as defined above, with a compound of formula XXXII,



XXXII

wherein R^1 is H;

(vi) for compounds of formula Iyd in which A represents a nitrogen-containing Het^{AA} group that is attached *via* a nitrogen atom within the ring system, reaction of a compound of formula VII,



VII

wherein X^{2a} represents a suitable leaving group, L^2 represents a direct bond, R^1 represents H, and B is as defined above, with a compound of formula XXXIII,

Het^{A1}—H XXXIII

wherein Het^{A1} takes the same definition as Het^{AA} as defined above, except that Het^{A1} is a nitrogen-containing heterocycle that is attached to the H-atom depicted for the compound of formula XXXIII *via* a nitrogen atom in the heterocycle;

(vii) for compounds of formula Iyd in which B represents a nitrogen-containing Het^{BB} group that is attached *via* a nitrogen atom within the ring system, reaction of a compound of formula XIX,



XIX

wherein X^{4a} represents a suitable leaving group, L^1 represents a direct bond, R^1 represents H, and A represents the requisite substituted pyridine-4-yl group as defined above, with a compound of formula XXXIV,

Het^{B1}—H XXXIV

wherein Het^{B1} takes the same definition as Het^{BB} as defined above, except that Het^{B1} is a nitrogen-containing heterocycle that is attached to the H-atom depicted for the compound of formula XXXIV *via* a nitrogen atom in the heterocycle; and

(ix) for compounds of formula Iyd in which one of $R^{4b'}$ R^{4b}, R^{4c} and R^{4d} represents -OH, reaction of a compound of formula Iyd in which one of R4b', R^{4b}, R^{4c} and R^{4d} represents -OR^{4y}, wherein R^{4y} represents a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-6} cycloalkyl, which groups are optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl and aryl, with a dealkylating agent.

References herein (in any aspect or embodiment of the disclosure~~invention~~) to compounds of formula I includes references to such compounds *per se*, to tautomers of such compounds, as well as to pharmaceutically acceptable salts or solvates, or pharmaceutically functional derivatives of such compounds.

Pharmaceutically acceptable salts that may be mentioned include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. *in vacuo*, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of formula I in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

Examples of pharmaceutically acceptable salts include acid addition salts derived from mineral acids and organic acids, and salts derived from metals such as sodium, magnesium, or preferably, potassium and calcium.

Examples of acid addition salts include acid addition salts formed with acetic, 2,2-dichloroacetic, adipic, alginic, aryl sulfonic acids (e.g. benzenesulfonic, naphthalene-2-sulfonic, naphthalene-1,5-disulfonic and *p*-toluenesulfonic), ascorbic (e.g. L-ascorbic), L-aspartic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulfonic, (+)-(1*S*)-camphor-10-sulfonic, capric, caproic, caprylic, cinnamic, citric, cyclamic, dodecylsulfuric, ethane-1,2-disulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, formic, fumaric, galactaric, gentisic, glucoheptonic, gluconic (e.g. D-gluconic), glucuronic (e.g. D-glucuronic), glutamic (e.g. L-glutamic), α-oxoglutaric, glycolic, hippuric, hydrobromic, hydrochloric, hydriodic, isethionic, lactic (e.g. (+)-L-lactic and (±)-DL-lactic), lactobionic, maleic, malic (e.g. (-)-L-malic), malonic, (±)-DL-mandelic, metaphosphoric, methanesulfonic, 1-hydroxy-2-naphthoic, nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulfuric, tannic, tartaric (e.g.(+)-L-tartaric), thiocyanic, undecylenic and valeric acids.

Particular examples of salts are salts derived from mineral acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids; from organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic,

Claims

1. A compound of formula A1:



A1

wherein:

A represents Cy^{AA} or Het^{AA};

Cy^{AA} represents a 6-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system, which Cy^{AA} group is substituted, in the 3-position relative to the point of attachment to the triazine ring, with a R^{4a} substituent and is optionally substituted by one or more additional R^{4a} substituents;

Het^{AA} represents a 6-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, and which Het^{AA} group is substituted, in the 3-position relative to the point of attachment to the triazine ring, with a R^{4b} substituent and is optionally substituted by one or more additional R^{4b} substituents;

B represents a Cy^{BB} or Het^{BB};

Cy^{BB} represents phenyl optionally substituted by one or more R^{4c} substituents;

Het^{BB} represents a 6-membered aromatic heterocyclic group which contains one or more N atoms, and which Het^{BB} group is optionally substituted by one or more R^{4d} substituents;

R^{4a} to R^{4d} represent, independently at each occurrence,

(a) halo,

(b) CN,

(c) C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy),

OR^{5a}, $S(O)_qR^{5b}$, $S(O)_2N(R^{5c})(R^{5d})$, $N(R^{5e})S(O)_2R^{5f}$, $N(R^{5g})(R^{5h})$, B^1-$C(G^1)$-B^2-R^{5i}, aryl and Het^1,

(d) Cy^3, which Cy^3 group is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{6a}, $S(O)_qR^{6b}$, $S(O)_2N(R^{6c})(R^{6d})$, $N(R^{6e})S(O)_2R^{6f}$, $N(R^{6g})(R^{6h})$, B^3-$C(G^1)$-B^4-R^{6i}, aryl and Het^2,

(e) Het^a, which Het^a group is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{7a}, $S(O)_qR^{7b}$, $S(O)_2N(R^{7c})(R^{7d})$, $N(R^{7e})S(O)_2R^{7f}$, $N(R^{7g})(R^{7h})$, B^5-$C(G^1)$-B^6-R^{7i}, aryl and Het^3,

(f) OR^8,

(g) $S(O)_rR^{9a}$,

(h) $S(O)_2N(R^{9b})(R^{9c})$,

(i) $N(R^{9d})S(O)_2R^{9e}$,

(j) $N(R^{9f})(R^{9g})$,

(k) B^7-$C(G^1)$-B^8-R^{9h},

(l) =O,

(m) =S,

or when two R^{4a}, R^{4b}, R^{4c} or R^{4d} groups are attached to the same carbon atom in a non-aromatic portion of a Cy^{AA}, Het^{AA}, Cy^{BB} or Het^{BB} group, they may form, together with the carbon atom to which they are attached, a saturated or unsaturated 3 to 6-membered ring, which ring optionally contains one to three heteroatoms selected from O, S and N, and which ring is optionally substituted by one or more R^{9i} substituents;

G^1 represents, independently at each occurrence, O, S or NR^{5j};

R^8 represents, independently at each occurrence,

H,

Cy^3, Het^a, $aryl^a$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-8} cycloalkyl, which latter seven groups are optionally substituted by one or more substituents selected from halo, -CN, C_{3-6} cycloalkyl, aryl, Het^4, $-C(O)OR^{10}$, $-C(O)R^{11}$, $-C(O)N(R^{N1})(R^{N2})$, $S(O)_rR^{9aa}$, $S(O)_2N(R^{9ba})(R^{9ca})$, $N(R^{9da})S(O)_2R^{9ea}$ and $N(R^{9fa})(R^{9ga})$;

Cy^3 represents, independently at each occurrence, a 3- to 6-membered aromatic, fully saturated or partially unsaturated carbocyclic ring;

Het^a represents, independently at each occurrence, a 3- to 6-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N;

R^{10} and R^{11} independently represent

(a) H,

(b) C_{1-6} alkyl optionally substituted by one or more substituents selected from halo, aryl, $-N(R^{N3})(R^{N4})$ and $-OR^a$,

(c) aryl or

(d) C_{3-7} cycloalkyl (which group is optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

B^1 to B^8 independently represent, at each occurrence, a direct bond, O, S or $N(R^{N3})$;

each $aryl^a$ independently represents a C_{6-14} carbocyclic aromatic group, which group may comprise one, two or three rings;

each aryl independently represents a C_{6-14} carbocyclic aromatic group, which group may comprise one, two or three rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N4})(R^{N5})$ and $-OR^a$, and

$-OR^a$;

Het^1 to Het^4 independently represent 4- to 14-membered heterocyclic groups containing one or more heteroatoms selected from O, S and N, which heterocyclic groups may comprise one, two or three rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N6})(R^{N7})$ and $-OR^a$, and

$-OR^a$;

R^{N1} to R^{N7} independently represent

H,

C_{1-6} alkyl or C_{3-6} cycloalkyl, which latter two groups are optionally substituted by one or more substituents selected from halo and $-OR^a$;

R^a represents, independently at each occurrence,

(a) H;

(b) C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{3-12} cycloalkyl, C_{4-12} cycloalkenyl, which latter five groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl (which latter four groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{12a}, $S(O)_qR^{12b}$, $S(O)_2N(R^{12c})(R^{12d})$, $N(R^{12e})S(O)_2R^{12f}$, $N(R^{12g})(R^{12h})$, B^9-$C(G^2)$-B^{10}-R^{12i}, $aryl^1$ and Het^b, and which C_{3-12} cycloalkyl or C_{4-12} cycloalkenyl groups may additionally be substituted by =O,

(c) $S(O)_rR^{13a}$,

(d) $S(O)_2N(R^{13b})(R^{13c})$ or

(e) $C(O)$-B^{11}-R^{13d};

R^{5a} to R^{5j}, R^{6a} to R^{6i}, R^{7a} to R^{7i}, R^{9a} to R^{9i}, R^{9aa} to R^{9ga}, R^{12a} to R^{12i} and R^{13a} to R^{13d} independently represent, at each occurrence,

(a) H,

(b) C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{5aa}, $S(O)_qR^{5ab}$, $S(O)_2N(R^{5ac})(R^{5ad})$, $N(R^{5ae})S(O)_2R^{5af}$, $N(R^{5ag})(R^{5ah})$, B^{12}-$C(G^2)$-B^{13}-R^{5ai}, $aryl^1$ and Het^c;

(c) C_{3-10} cycloalkyl, or C_{4-10} cycloalkenyl (which latter two groups are optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-6} alkyl and C_{1-6} alkoxy),

(d) Het^d;

G^2 represents, independently at each occurence, O, S, or NR^{5aj};

R^{5aa} to R^{5aj} independently represent at each occurrence,

(a) H,

(b) C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-4} alkyl,

C_{2-4} alkenyl, C_{2-4} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy),

(c) C_{3-6} cycloalkyl, or C_{4-6} cycloalkenyl (which latter two groups are optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-4} alkyl and C_{1-4} alkoxy),

(d) Het^{e},

or R^{5ag} and R^{5ah} may represent, together with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which may additionally contain one or more heteroatoms selected from O, S and N, which heterocyclic ring is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

B^{9} to B^{13} independently represent a direct bond, O, S or $N(R^{N8})$;

$aryl^{1}$ represents, independently at each occurrence, a C_{6-10} carbocyclic aromatic group, which group may comprise one or two rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N10})(R^{N11})$ and C_{1-6} alkoxy (which latter substituent is optionally substituted by one or more halo atoms), and

C_{1-6} alkoxy (which latter substituent is optionally substituted by one or more halo atoms);

R^{N8}, R^{N10} and R^{N11} independently represent

H,

C_{1-6} alkyl or C_{3-6} cycloalkyl, which latter two groups are optionally substituted by one or more halo atoms;

Het^{b} represents a 5- or 6-membered that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may be substituted by one or more substituents selected from halo, =O and C_{1-6} alkyl;

Het^c to Het^e independently represent, a 3- to 6-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N, which Het^c to Het^e groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

q and r independently represent at each occurrence 0, 1 or 2; and
unless otherwise specified alkyl, alkenyl, alkynyl, cycloalkyl and the alkyl part of alkoxy groups may be substituted by one or more halo atoms;

or a pharmaceutically acceptable salt or solvate, or a pharmaceutically functional derivative thereof,

provided that the compound is not:

(a) 5-(2-chlorophenyl)-6-(3,4-dimethoxyphenyl)-[1,2,4]triazin-3-ylamine; or

(b) 5-(2-chlorophenyl)-6-(3,4,5-trimethoxyphenyl)-[1,2,4]triazin-3-ylamine.

2. A compound as claimed in Claim 1, wherein A represents $Cy^{AA'}$, $Het^{AA'}$, $Het^{AA''}$ or $Het^{AA'''}$, and

$Cy^{AA'}$ represents a 6-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system, which $Cy^{AA'}$ group is substituted, in the 3-position relative to the point of attachment to the triazine ring, with a R^{4a} substituent and is substituted in the 4-position relative to the point of attachment to the triazine ring, with a OR^8 substituent and is optionally further substituted by one or more additional R^{4a} substituents;

$Het^{AA'}$ represents a 6-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, and which $Het^{AA'}$ group is substituted, in the 3-position relative to the point of attachment to the triazine ring, with a R^{4b} substituent and is substituted, in the 4-position relative to the point of attachment to the triazine ring, with a OR^8 substituent, and is optionally further substituted by one or more additional R^{4b} substituents;

$Het^{AA''}$ represents a 6-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains, in the 4-position relative to the point of attachment to the triazine ring, a N-atom, and which group optionally contains one or

more further heteroatoms selected from O, S and N, which $Het^{AA''}$ group is substituted, in the 3-position relative to the point of attachment to the triazine ring, with a R^{4b} substituent and is optionally substituted by one or more additional R^{4b} substituents; and

$Het^{AA'''}$ represents a 6-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which $Het^{AA'''}$ group is substituted, in the 3-position relative to the point of attachment to the triazine ring, with a R^{4b} substituent and is substituted, in the 4-position relative to the point of attachment to the triazine ring, with an oxo (=O) group, and is optionally further substituted by one or more additional R^{4b} substituents.

3. A compound as claimed in Claim 1 or Claim 2, wherein:

when A represents Cy^A or $Cy^{AA'}$, that 6-membered carbocyclic ring is further substituted, in the 5-position relative to the point of attachment to the triazine ring, with a R^{4a} substituent; or

when A represents Het^{AA} or $Het^{AA'}$, $Het^{AA''}$ or $Het^{AA'''}$, that 6-membered heterocyclic ring is further substituted, in the 5-position relative to the point of attachment to the triazine ring, with a R^{4b} substituent.

4. A compound as claimed in any one of Claims 1 to 3, wherein,

(1) R^{4a} and R^{4b} represent, independently at each occurrence,

halo,

CN,

C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl (which latter groups are optionally substituted by one or more substituents selected from aryl, halo and OR^{5a}),

Cy^3 optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-3} alkyl (which group is optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-3} alkyl and C_{1-3} alkoxy), OR^{6a}, $S(O)_qR^{6b}$, $S(O)_2N(R^{6c})(R^{6d})$, $N(R^{6e})S(O)_2R^{6f}$, $N(R^{6g})(R^{6h})$, B^3-$C(G^1)$-B^4-R^{6i} and aryl,

Het^a optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-3} alkyl (which group is optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-3} alkyl and C_{1-3} alkoxy), OR^{7a}, $S(O)_qR^{7b}$, $S(O)_2N(R^{7c})(R^{7d})$, $N(R^{7e})S(O)_2R^{7f}$, $N(R^{7g})(R^{7h})$, B^5-$C(G^1)$-B^6-R^{7i} and aryl,

OR^8,

$S(O)_rR^{9a}$,

$N(R^{9f})(R^{9g})$,

B^7-$C(G^1)$-B^8-R^{9h},

=O,

or when two R^{4a} or R^{4d} groups are attached to the same carbon atom in a non-aromatic Cy^1, Cy^{AA}, Het^A or Het^{AA}, group, they may form, together with the carbon atom to which they are attached, a saturated or unsaturated 5-membered ring, which ring optionally contains one or two heteroatoms selected from O and N, and which ring is optionally substituted by one or more R^{9i} substituents;

(2) R^{4c} and R^{4b} represent, independently at each occurrence,

halo

CN,

C_{1-3} alkyl (which latter group is optionally substituted by one or more substituents selected from halo and OR^{5a}),

OR^8,

$N(R^{9f})(R^{9g})$ or

B^7-$C(G^1)$-B^8-R^{9h}; and/or

(3) G^1 represents, independently at each occurrence, O.

5. A compound as claimed in any one of Claims 1 to 4, wherein:

(1) R^8 represents, independently at each occurrence,

H,

Cy^3, Het^a, $aryl^a$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, which latter seven groups are optionally substituted by one or more substituents selected from halo, -CN, C_{3-6} cycloalkyl, aryl, Het^4, $-C(O)OR^{10}$, $-C(O)R^{11}$ and $-C(O)N(R^{N1})(R^{N2})$, $S(O)_rR^{9aa}$, $S(O)_2N(R^{9ba})(R^{9ca})$, $N(R^{9da})S(O)_2R^{9ea}$ and $N(R^{9fa})(R^{9ga})$;

(2) each $aryl^a$ independently represents a C_{6-10} carbocyclic aromatic group, which group may comprise one or two rings;

(3) each aryl independently represents a C_{6-10} carbocyclic aromatic group, which group may comprise one or two rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N4})(R^{N5})$ and $-OR^a$, and

$-OR^a$;

(4) R^a represents, independently at each occurrence,

H,

C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{4-6} cycloalkenyl (which latter five groups are optionally substituted by one or more substituents selected

from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl (which latter four groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{12a}, $S(O)_qR^{12b}$, $S(O)_2N(R^{12c})(R^{12d})$, $N(R^{12e})S(O)_2R^{12f}$, $N(R^{12g})(R^{12h})$, B^9-$C(G^2)$-B^{10}-R^{12i}, $aryl^1$ and Het^b, and which C_{3-6} cycloalkyl or C_{4-6} cycloalkenyl groups may additionally be substituted by =O),

$S(O)_rR^{13a}$,

$S(O)_2N(R^{13b})(R^{13c})$ or

$C(O)$-B^{11}-R^{13d};

(5) R^{5a} to R^{5j}, R^{6a} to R^{6i}, R^{7a} to R^{7i}, R^{9a} to R^{9i}, R^{9aa} to R^{9ga}, R^{12a} to R^{12i} and R^{13a} to R^{13d} independently represent, at each occurrence,

H,

C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from halo, OH and C_{1-4} alkoxy),

C_{3-6} cycloalkyl or C_{4-6} cycloalkenyl (which latter two groups are optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-6} alkyl and C_{1-6} alkoxy),

Het^d; and/or

(6) G^2 represents, independently at each occurrence, O.

6. Compound as claimed in Claim 5, wherein:

(1) R^8 represents, independently at each occurrence,

H,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, -CN, C_{3-6} cycloalkyl, aryl, Het^4, $-C(O)OR^{10}$, $-C(O)R^{11}$ and $-C(O)N(R^{N1})(R^{N2})$;

(2) B^1 to B^8 independently represent a direct bond or $N(R^{N3})$;

(3) each aryl independently represents a phenyl group that is optionally substituted by one or more substituents selected from

halo,

C_{1-3} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N4})(R^{N5})$ and $-OR^a$, and

$-OR^a$;

(4) R^{N1} to R^{N7} independently represent

H,

C_{1-3} alkyl or C_{3-5} cycloalkyl, which latter two groups are optionally substituted by one or more substituents selected from halo and $-OR^a$;

(5) R^a represents independently at each occurrence,

H,

C_{1-3} alkyl, (which latter group is optionally substituted by one or more substituents selected from halo, OH and C_{1-4} alkoxy) or

C_{3-6} cycloalkyl (which latter group is optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-6} alkyl and C_{1-4} alkoxy); and/or

(6) R^{10} and R^{11} independently represent

H,

C_{1-3} alkyl optionally substituted by one or more substituents selected from halo, aryl, $-N(R^{N3})(R^{N4})$ and $-OR^a$,

phenyl (which latter group is optionally substituted by one or more substituents selected from OH, halo, C_{1-4} alkyl and C_{1-4} alkoxy) or

C_{3-6} cycloalkyl (which latter group is optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy).

7. Compound as claimed in any one of Claims 1 to 6, wherein A is a 6-membered Cy^1, Cy^{AA}, Het^A or Het^{AA} group that has:

- no substituents in the *ortho*-positions;
- a substituent in one or both of the *meta*-positions; and, optionally
- a substituent in the *para*-position,

wherein the substituents are as defined in Claims 1 to 5 for groups Cy^1, Cy^{AA}, Het^A or Het^{AA}.

8. A compound as claimed in any one of Claims 1 to 7, wherein the compound of formula A1 is represented by a compound of formula Ixd, Iyd or Izd,



respectively, wherein:

rr1 represents 0 or 1;

rr2 and rr3 independently represent 0 or 1;

ss and tt independently represent, at each occurrence 0 or 1, provided that ss and tt do not both represent 0;

$R^{4a'}$ takes the same definition as R^{4a};

$R^{4b'}$ takes the same definition as R^{4b};

L^1 and L^2 both represent direct bonds; and

B, R^{4a} and R^{4b} are as defined in any one of Claims 1 to 6.

9. Compound as claimed in any one of Claims 1 to 8, wherein:

R^{4a} and R^{4b} represent, independently at each occurrence, cyclopropyl, iodo, bromo, chloro, fluoro, ethyl, methyl, d_3-methyl, iso-propyl, -C≡CH, phenyl, CF_3, CHF_2, CH_2F, CH_2CF_3, CF_2CF_3, CN, =O, OH, $OCH(CH_3)_2$, OCH_3, OCH_2CH_3, OCH_2F, $OCHF_2$, OCH_2CF_3, OCF_3, $(CH_2)_3OH$, CH_2OH or CH_2OCH_3, $CH(CH_3)OH$, $C(CH_3)_3OH$, CH_2CH_2OH, NH_2, $N(CH_3)_2$, $N(H)CH_2CH_3$, $N(H)C(O)CH_3$, $C(O)CH_3$, $C(O)N(CH_3)_2$, $S(O)_2CH_3$, $S(O)CH_3$, SCH_3, $S(O)_2CF_3$, azetidine, morpholine or dioxolane.

10. Compound as claimed in any one of Claims 1 to 9, wherein the compound of formula A1 is selected from the list comprising:

(iii) 6-(3-methoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(v) 6-(5-chloro-2-methoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(vi) 6-(3-chlorophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xiii) 6-(3-methylpiperidin-1-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xix) 6-(3-chlorophenyl)-5-(2,4-difluorophenyl)-1,2,4-triazin-3-amine;

(xx) 5-phenyl-6-(3,4,5-trifluorophenyl)-1,2,4-triazin-3-amine;

(xxi) 6-(2,6-dimethylmorpholin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xxiii) 6-(3-chlorophenyl)-5-(3-methoxyphenyl)-1,2,4-triazin-3-amine;

(xxiv) 5-phenyl-6-[3-(trifluoromethyl)phenyl]-1,2,4-triazin-3-amine;

(xxv) 6-(3,5-difluorophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xxvii) 6-[3-fluoro-5-(trifluoromethyl)phenyl]-5-phenyl-1,2,4-triazin-3-amine;

(xxviii) 6-(3,5-dichlorophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xxix) 6-(5-chloropyridin-3-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xxx) 6-(3-chloro-4-fluorophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xxxi) 6-(3-fluoro-5-methoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xxxiv) 6-(3-chlorophenyl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(xxxv) 6-(3-chloro-5-methoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xxxviii) 6-(3,3-dimethylpiperidin-1-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xxxix) 6-(3-bromophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xli) 5-phenyl-6-[3-(trifluoromethyl)piperidin-1-yl]-1,2,4-triazin-3-amine;

(xlv) 6-(3,4-dichlorophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xlvi) 6-(3-fluorophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xlviii) 3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)benzonitrile;

(xlix) 6-(3,5-dimethoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(l) 6-(3,5-dimethylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(li) 6-(3,4-dimethylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(liii) 6-[3-(dimethylamino)phenyl]-5-phenyl-1,2,4-triazin-3-amine;

(liii) N-[3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)phenyl]acetamide;

(liv) N-[3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)phenyl]methanesulfonamide;

(lv) 6-(3-trifluoromethoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lvii) 5-phenyl-6-[3-(propan-2-yl)phenyl]-1,2,4-triazin-3-amine;

(lviii) 6-(3,5-dichlorophenyl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(lix) 6-(3,5-bis(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lx) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-methoxyphenol;

(lxi) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2,6-dimethylphenol;

(lxii) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol;

(lxiii) 6-(2-chloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(lxiv) 6-(3-(methylsulfonyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxv) 6-(3,5-dichloro-4-methoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxvi) 6-(4-methoxy-3-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxvii) 6-(3-chloro-5-(dimethylamino)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxviii) 3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-5-(trifluoromethyl)benzonitrile;

(lxix) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(lxx) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxi) 6-(3-chloro-5-methylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxii) 6-(3-(methylthio)-5-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxiii) 6-(3-methoxy-5-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxiv) 6-(3-ethoxy-5-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxv) 6-(3-tert-butyl-5-methylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxvi) 6-(2-chloro-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxvii) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorobenzonitrile;

(lxxviii) 6-(3-ethylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxix) 6-(2-methoxy-6-(trifluoromethyl)pyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxx) 6-(3-methyl-5-(trifluoromethoxy)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxxi) 6-(3-(1,3-dioxolan-2-yl)-5-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxxii) 5-phenyl-6-(3-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-triazin-3-amine;

(lxxxiii) 6-(3-(methoxymethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxxiv) 5-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-1-methylpyridin-2(1H)-one;

(lxxxv) 6-(3-methyl-5-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxxvi) 6-(2-methoxypyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxxvii) 1-(3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)phenyl)ethanone;

(lxxxix) 6-(4-fluoro-3-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xc) 6-(4-fluoro-3-methylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xci) 6-(3-bromo-5-chlorophenyl)-5-phenyl-1,2,4-triazin-3-amine;

(xciii) 5-phenyl-6-m-tolyl-1,2,4-triazin-3-amine;

(xcvi) 6-(2,6-dimethoxypyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xcvii) 6-(2,6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xcviii) 5-phenyl-6-(2-(trifluoromethyl)pyridin-4-yl)-1,2,4-triazin-3-amine;

(xcix) 6-(2-cyclopropylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(c) 5-phenyl-6-(2,2,6,6-tetramethyl-3,6-dihydro-2H-pyran-4-yl)-1,2,4-triazin-3-amine;

(ci) 6-(5-chloro-2-fluoro-3-methylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(cii) 6-(2,6-dichloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ciii) 6-(3-bromo-5-(trifluoromethoxy)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(civ) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chloro-6-methoxyphenol;

(cv) 6-(3,5-dichloro-4-ethoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(cvi) 6-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cvii) 4-(3-amino-5-(3-fluorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cviii) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(cix) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(cx) 4-(3-amino-5-(4-fluorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cxi) 6-(3-chloro-5-propoxyphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(cxii) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cxiii) 6-(2-chloropyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cxiv) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cxv) 4-(3-amino-5-(4-chlorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cxvi) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(4-chlorophenyl)-1,2,4-triazin-3-amine;

(cxvii) 5-(4-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(cxviii) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-chlorophenyl)-1,2,4-triazin-3-amine;

(cxix) 4-(3-amino-5-(3-chlorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cxx) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3-chlorophenyl)-1,2,4-triazin-3-amine;

(cxxi) 5-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxii) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3-chlorophenyl)-1,2,4-triazin-3-amine;

(cxxiii) 4-(3-amino-6-(3-chloro-5-(trifluoromethyl)phenyl)-1,2,4-triazin-5-yl)benzonitrile;

(cxxiv) 4-(3-amino-6-(2-chloro-6-methylpyridin-4-yl)-1,2,4-triazin-5-yl)benzonitrile;

(cxxv) 4-(3-amino-5-(3-chloro-5-fluorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cxxvi) 5-(3-chloro-5-fluorophenyl)-6-(2-chloro-6-methylpyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxvii) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3-chloro-5-fluorophenyl)-1,2,4-triazin-3-amine;

(cxxviii) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;

(cxxix) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;

(cxxx) 4-(3-amino-5-(3,5-difluorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cxxxi) 4-(3-amino-5-(3-chloro-4-fluorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cxxxii) 5-(3-chloro-4-fluorophenyl)-6-(2-chloro-6-methylpyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxxiii) 5-(3-chloro-4-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxxiv) 5-(3-chloro-4-fluorophenyl)-6-(3-chloro-5-(trifluoromethyl)phenyl)-1,2,4-triazin-3-amine;

(cxxxv) 4-(3-amino-5-(3,4-difluorophenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(cxxxvi) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3,4-difluorophenyl)-1,2,4-triazin-3-amine;

(cxxxvii) 6-(2-chloropyridin-4-yl)-5-(3,4-difluorophenyl)-1,2,4-triazin-3-amine;

(cxxxviii) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3,4-difluorophenyl)-1,2,4-triazin-3-amine;

(cxxxix) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-3-amine;

(cxl) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-3-amine;

(cxli) 6-(2,6-dimethylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cxlii) 6-(3-chloro-5-methylphenyl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cxlv) 6-(3,5-diisopropylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(cxlvi) 6-(3-fluoro-5-(2,2,2-trifluoroethoxy)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(cxlvii) N-(4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-(trifluoromethyl)phenyl)acetamide;

(cxlviii) 5-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-fluorobenzonitrile;

(cxlix) 3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-N,N-dimethylbenzamide;

(cli) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-1-methylpyridin-2(1H)-one;

(clii) 6-(3-(morpholin-4-yl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(clvi) 6-(3-(methylsulfinyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(clvii) 4-(3-amino-6-(2-chloropyridin-4-yl)-1,2,4-triazin-5-yl)benzonitrile;

(clviii) 4-(3-amino-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(clix) 6-(2-chloropyridin-4-yl)-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-3-amine;

(clxiii) 6-(3-methoxypiperidin-1-yl)-5-phenyl-1,2,4-triazin-3-amine;

(clxiv) 6-(3-ethynylpiperidin-1-yl)-5-phenyl-1,2,4-triazin-3-amine;

(clxv) 6-(2,6-dimethylmorpholin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(clxvi) 6-(2-ethylmorpholino)-5-phenyl-1,2,4-triazin-3-amine;

(clxvii) 5-phenyl-6-(6-oxa-9-azaspiro[4.5]decan-9-yl)-1,2,4-triazin-3-amine;

(clxviii) 6-(2,2-diethylmorpholino)-5-phenyl-1,2,4-triazin-3-amine;

(clxix) 6-(2,2-dimethylmorpholino)-5-phenyl-1,2,4-triazin-3-amine;

(clxx) (1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-3-methylpiperidin-3-yl)methanol;

(clxxi) 6-(3-(methoxymethyl)piperidin-1-yl)-5-phenyl-1,2,4-triazin-3-amine;

(clxxii) 1-(1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)piperidin-3-yl)ethanol ;

(clxxiii) (1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)piperidin-3-yl)methanol;

(clxxiv) 1-(1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)piperidin-3-yl)ethanone;

(clxxviii) 5-phenyl-6-(3-phenylpiperidin-1-yl)-1,2,4-triazin-3-amine;

(clxxix) (4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)morpholin-2-yl)methanol;

(clxxxi) 2-(1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)piperidin-3-yl)propan-2-ol;

(clxxxiii) 1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-3-ethylpiperidin-3-ol;

(clxxxiv) 2-(4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)morpholin-2-yl)ethanol;

(clxxxvii) 1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)pyridin-4(1H)-one;

(cxcvii) 1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)pyridazin-4(1H)-one;

(cxcviii) 1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-3,5-dichloropyridin-4(1H)-one;

(cciii) 3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-5-chlorophenol;

(cciv) 6-(3-chloro-5-ethenylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(ccv) 6-(3-chloro-5-cyclopropylphenyl)-5-phenyl-1,2,4-triazin-3-amine;

(ccviii) 5-(3-chloro-5-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(ccix) 6-(2-chloropyridin-4-yl)-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;

(ccx) 4-(3-amino-5-(4-(difluoromethoxy)phenyl)-1,2,4-triazin-6-yl)-2,6-dimethylbenzonitrile;

(ccxi) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-(difluoromethoxy)phenyl)-1,2,4-triazin-3-amine;

(ccxii) 6-(2-chloropyridin-4-yl)-5-(4-(difluoromethoxy)phenyl)-1,2,4-triazin-3-amine;

(ccxiii) 6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(4-(difluoromethoxy)phenyl)-1,2,4-triazin-3-amine;

(ccxiv) 5-(3-amino-5-(3-fluorophenyl)-1,2,4-triazin-6-yl)-2-chlorophenol;

(ccxv) 4-[3-amino-6-(3-chloro-4-hydroxyphenyl)-1,2,4-triazin-5-yl]benzonitrile ;

(ccxvi) 3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-5-(trifluoromethoxy)phenol;

(ccxvii) 5-(3-chloro-5-fluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxviii) 5-(3,5-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxix) 5-(3,4-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxx) 5-(3-chloro-4-fluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxi) 5-(4-(difluoromethoxy)phenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxii) 6-(2,6-dimethylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(ccxxiii) 5-(4-chlorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxiv) 4-(3-amino-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-5-yl)benzonitrile;

(ccxxv) 5-(3-chlorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxvi) 6-(2,6-dimethylpyridin-4-yl)-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-3-amine;

(ccxxvii) 4-(3-amino-6-(3-chloro-4-hydroxy-5-methoxyphenyl)-1,2,4-triazin-5-yl)benzonitrile;

(ccxxviii) 5-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol;

(ccxxix) 6-(6-chloropyridin-2-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxxx) 6-(4-cyclopropylpyridin-2-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxxxi) 5-phenyl-6-(6-(trifluoromethyl)pyridin-2-yl)-1,2,4-triazin-3-amine;

(ccxxxii) 5-phenyl-6-(4-(trifluoromethyl)pyridin-2-yl)-1,2,4-triazin-3-amine;

(ccxxxiii) 6-(6-cyclopropylpyridin-2-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxxxv) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2,6-diiodophenol;

(ccxxxvi) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-iodophenol;

(ccxxxvii) 6-(3-methoxy-5-(trifluoromethoxy)phenyl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxxxviii) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-(propan-2-yloxy)phenol;

(ccxxxix) 5-(3-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxli) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(3,4-difluorophenyl)-1,2,4-triazin-3-amine;

(ccxlii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;

(ccxliii) 6-[2-(ethylamino)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccxliv) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(ccxlv) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(ccxlvi) 6-{2-[ethyl(methyl)amino]-6-methylpyridin-4-yl}-5-phenyl-1,2,4-triazin-3-amine;

(ccxlvii) 6-[2-(dimethylamino)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccxlviii) 1-[6-(2,6-d6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxlix) 6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccl) 5-(4-fluorophenyl)-6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(ccli) 6-(2,6-dimethylpyridin-4-yl)-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(cclii) 6-(2-chloro-6-methylpyridin-4-yl)-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(ccliii) 6-(2,6-dimethylpyridin-4-yl)-5-(4-methoxyphenyl)-1,2,4-triazin-3-amine;

(ccliv) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-methoxyphenyl)-1,2,4-triazin-3-amine;

(cclv) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclvi) 6-[2-chloro-6-(difluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclvii) 6-[2-chloro-6-(fluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclviii) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cclix) 6-[2,6-bis(fluoromethyl)pyridine-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclx) 6-[2-(fluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxi) 6-(2-chloro-6-methylpyridin-4-yl)-5-(2,5-difluorophenyl)-1,2,4-triazin-3-amine;

(cclxii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxiii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2,5-difluorophenyl)-1,2,4-triazin-3-amine;

(cclxiv) 6-[2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxv) 6-[2-ethyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxvi) 6-(2-cyclopropyl-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cclxvii) 5-(2-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxviii) 5-(3-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxix) 5-(4-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxx) 5-(2,5-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxxi) 5-(3,4-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxxii) 5-(3,5-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxxiii) 6-[2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxxiv) 6-[2-methyl-6-(morpholin-4-yl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxv) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-ethylphenyl)-1,2,4-triazin-3-amine;

(cclxxvi) 5-(2,5-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(cclxxvii) 6-(2,6-dimethylpyridin-4-yl)-5-(4-methylphenyl)-1,2,4-triazin-3-amine;

(cclxxviii) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxxix) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxxx) 6-(3,5-dichlorophenyl)-5-(pyridin-2-yl)-1,2,4-triazin-3-amine;

(cclxxxi) 6-(3-chloro-5-methylphenyl)-5-(pyridin-2-yl)-1,2,4-triazin-3-amine;

(cclxxxii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxiii) 6-[2,6-bis(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxiv) 6-[3-chloro-5-(trifluoromethyl)phenyl]-5-(pyridin-2-yl)-1,2,4-triazin-3-amine;

(cclxxxv) 6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxvi) 6-(3,5-dimethylphenyl)-5-(pyridin-2-yl)-1,2,4-triazin-3-amine;

(cclxxxvii) 6-[2-(dimethylamino)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxviii) 6-(2-bromo-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxix) 6-(2,6-dimethyl-1-oxidopyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxc) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-6-methylpyridine-2-carbonitrile;

(ccxci) 6-(3,5-dichlorophenyl)-5-(pyridin-3-yl)-1,2,4-triazin-3-amine;

(ccxcii) 6-(3-chloro-5-methylphenyl)-5-(pyridin-3-yl)-1,2,4-triazin-3-amine;

(ccxciii) 6-(3,5-dichlorophenyl)-5-(pyrimidin-2-yl)-1,2,4-triazin-3-amine;

(ccxciv) 6-[3-chloro-5-(trifluoromethyl)phenyl]-5-(pyrimidin-2-yl)-1,2,4-triazin-3-amine;

(ccxcv) 6-[2-bromo-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
(ccxcvi) 6-[3-chloro-5-(trifluoromethyl)phenyl]-5-(pyridin-3-yl)-1,2,4-triazin-3-amine;
(ccxcvii) 6-(3-chloro-5-methylphenyl)-5-(pyrimidin-2-yl)-1,2,4-triazin-3-amine;
(ccxcviii) N-[5-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-methoxyphenyl]acetamide;
(ccxcix) N-[5-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-hydroxyphenyl]acetamide;
(ccc) 6-(2-methyl-6-d3-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
(ccci) 1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-3,5-dimethylpyridin-4(1H)-one;
(cccii) 6-[2-(azetidin-1-yl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
(ccciii) 6-[2-(azetidin-1-yl)-6-methylpyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; and
(ccciv) 6-[2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine.

11. A compound as claimed in any one of Claims 1 to 10, wherein the compound of formula A1 is selected from:
6-(3,5-dichlorophenyl)-5-phenyl-1,2,4-triazin-3-amine;
6-(3,5-bis(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;
6-(2-chloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
6-(3-chloro-5-methylphenyl)-5-phenyl-1,2,4-triazin-3-amine;
6-(2-chloro-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
6-(3-methyl-5-(trifluoromethyl)phenyl)-5-phenyl-1,2,4-triazin-3-amine;
6-(2-methoxypyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
6-(3-bromo-5-chlorophenyl)-5-phenyl-1,2,4-triazin-3-amine;
6-(2,6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
5-phenyl-6-(2-(trifluoromethyl)pyridin-4-yl)-1,2,4-triazin-3-amine;
6-(2-cyclopropylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
6-(2,6-dichloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;
6-(2-chloro-6-methylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;
6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(4-chlorophenyl)-1,2,4-triazin-3-amine;
5-(4-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3-chlorophenyl)-1,2,4-triazin-3-amine;
5-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
6-(3-chloro-5-(trifluoromethyl)phenyl)-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;
5-(3-chloro-4-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
6-(2,6-dimethylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
6-(3-chloro-5-methylphenyl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

1-(3-amino-5-phenyl-1,2,4-triazin-6-yl)pyridin-4(1H)-one;
3-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-5-(trifluoromethoxy)phenol;
5-(3,5-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;
6-(2,6-dimethylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;
5-(4-chlorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;
4-(3-amino-6-(3-chloro-4-hydroxy-5-methoxyphenyl)-1,2,4-triazin-5-yl)benzonitrile;
6-(4-cyclopropylpyridin-2-yl)-5-phenyl-1,2,4-triazin-3-amine;
4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-iodophenol;
4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-(propan-2-yloxy)phenol;
5-(3-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;6-(2-chloro-6-methylpyridin-4-yl)-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2,5-difluorophenyl)-1,2,4-triazin-3-amine;6-(2-cyclopropyl-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
5-(2-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
5-(3-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
5-(4-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
5-(3,5-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;6-[2-bromo-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-(azetidin-1-yl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2,6-dimethylphenol;
6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
5-(4-fluorophenyl)-6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-chloro-6-(difluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-chloro-6-(fluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-(fluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-(2-bromo-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine; and
N-[5-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-hydroxyphenyl]acetamide.

12. A compound selected from the group comprising:
6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine and
6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine,

or a pharmaceutically acceptable salt or solvate, or a pharmaceutically functional derivative thereof.

13. A compound as claimed in any one of Claims 1 to 12, wherein:
B represents a Cy^{BB} or Het^{BB} group, which group is either unsubstituted or is substituted by one or more substituents selected from fluoro, CN, OR^8 or C_{1-6} alkyl optionally substituted by one or more substituents selected from halo and OR^{5a}, wherein R^{5a} and R^8 are as defined in any one of Claims 1 to 9.

14. A compound as claimed in Claim 13, wherein:
B represents a Cy^{BB} or Het^{BB} group, which group is either unsubstituted or is substituted by fluoro at the 4-position relative to the point of attachment to the triazine ring.

15. A compound as claimed in any one of Claims 1 to 14, wherein:
R^{4a} is as defined in Claims 1 to 9 except that it does not represent OR^8 in which R^8 represents CH_3.

16. A compound of formula A1 as defined in any one of Claims 1 to 12 for use in the treatment of a condition or disorder ameliorated by the inhibition of the A_1 receptor or the A_{2a} receptor.

17. Use of a compound of formula A1 as defined in any one of Claims 1 to 12 for the manufacture of a medicament for the treatment of a condition or disorder ameliorated by the inhibition of the A_1 receptor or the A_{2a} receptor.

18. Compound for use as claimed in Claim 16, or use as claimed in Claim 17, wherein the condition or disorder ameliorated by the inhibition of the A_1 receptor or the A_{2a} receptor is selected from: heart failure; kidney failure; oedema; cancer; diabetes; diarrhea; macular degeneration; depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal

fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour.

19. The use or the compound for use as claimed in Claim 18, wherein the condition or disorder is ameliorated by the inhibition of the A_{2a} receptor and is selected from depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour.

20. The use or the compound for use as claimed in Claim 18 or Claim 19, wherein the condition or disorder is migraine.

21. The use or the compound for use as claimed in Claim 19, wherein the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease or amyotrophic lateral sclerosis.

22. The use or the compound for use as claimed in Claim 19 or Claim 21, wherein the condition or disorder ameliorated by the inhibition of the A_{2a} receptor is Parkinson's disease.

23. The use or the compound for use as claimed in Claim 19 or Claim 21, wherein the condition or disorder ameliorated by the inhibition of the A_{2a} receptor is addictive behaviour or ADHD.

24. The compound for use as claimed in Claim 16, or the use as claimed in Claim 17, wherein the condition or disorder ameliorated by the inhibition of the A_1 receptor is mitigation of kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

25. A compound of formula A1 as defined in any one of Claims 1 to 12 for use in mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

26. Use of compound of formula A1 as defined in any one of Claims 1 to 12 for the manufacture of a medicament for mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

27. The compound for use as claimed in Claim 25, or the use as claimed in Claim 26, wherein the compound of formula A1 is N-[5-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-hydroxyphenyl]acetamide.

28. A compound of formula A1 as claimed in any one of Claims 1 to 12 for use in medicine.

29. A pharmaceutical formulation including a compound of formula A1 as defined in any one of Claims 1 to 12 in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

30. A process for the preparation of a compound of formula A1 as defined in any one of Claims 1 to 12, which process comprises:

(i)(a) reaction of a compound of formula III,



III

wherein L^{x1a} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, wherein each R^{x1} mentioned herein independently represents a C_{1-6} alkyl group, or, in the case of $-B(OR^{x1})_2$, the two R^{x1} groups may be linked together to form a 4- to 6-membered cyclic group, L^2 represents a direct bond, R^1 represents H, and B is as defined in Claim 1, with a compound of formula IV,

$$A—X^{1a} \qquad IV$$

wherein X^{1a} represents a suitable leaving group, and A is as defined in Claim 1;

(b) reaction of a compound of formula V,



V

wherein X^{1b} represents a suitable leaving group, L^2 represents a direct bond, R^1 represents H, and B is as defined in Claim 1, with a compound of formula VI,

$$A—L^{x1b} \qquad VI$$

wherein L^{x1b} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, wherein each R^{x1} is as defined above, and A is as defined in Claim 1;

(ii)(a) reaction of a compound of formula XV,



XV

wherein L^{x3a} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, in which each R^{x1} is as defined above, L^1 represents a direct bond, R^1 represents H, and A is as defined in Claim 1, with a compound of formula XVI,

$$B—X^{3a} \qquad XVI$$

wherein X^{3a} represents a suitable leaving group and B is as defined in Claim 1;

(b) reaction of a compound of formula XVII,



XVII

wherein X^{3b} represents a suitable leaving group, L^1 represents a direct bond, R^1 represents H, and A is as defined in Claim 1, with a compound of formula XVIII,

$$B—L^{x3b} \qquad XVIII$$

wherein L^{x3b} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, in which each R^{x1} is as defined above, and B is as defined in Claim 1;

(iii) reaction of a compound of formula XXVIII,



XXVIII

wherein X^6 represents a suitable leaving group such, L^1 and L^2 represent direct bonds, and A and B are as defined in Claim 1, with a compound of formula XXIX,

R^1NH_2 XXIX

wherein R^1 is H;

(iv) reaction of a compound of formula XXX,



XXX

wherein R^{x2} represents a suitable leaving group, L^1 and L^2 represent direct bonds, and A and B are as defined in Claim 1, or a protected derivative thereof, with a compound of formula XXIX, wherein R^1 is H;

(v) reaction of a compound of formula XXXI,



XXXI

wherein A and B are as defined in Claim 1, with a compound of formula XXXII,



XXXII

wherein R^1 is H;

(vi) for compounds of formula A1 in which A represents a nitrogen-containing Het^{AA} group that is attached *via* a nitrogen atom within the ring system, reaction of a compound of formula VII,



VII

wherein X^{2a} represents a suitable leaving group, L^2 represents a direct bond, R^1 represents H, and B is as defined in Claim 1, with a compound of formula XXXIII,

Het^{A1}—H XXXIII

wherein Het^{A1} takes the same definition as Het^{AA} as defined above, except that Het^{A1} is a nitrogen-containing heterocycle that is attached to the H-atom depicted for the compound of formula XXXIII *via* a nitrogen atom in the heterocycle;

(vii) for compounds of formula A1 in which B represents a nitrogen-containing Het^{BB} group that is attached *via* a nitrogen atom within the ring system, reaction of a compound of formula XIX,



XIX

wherein X^{4a} represents a suitable leaving group, L^1 represents a direct bond, R^1 represents H, and A is as defined in Claim 1, with a compound of formula XXXIV,

Het^{B1}—H XXXIV

wherein Het^{B1} takes the same definition as Het^{BB} as defined above, except that Het^{B1} is a nitrogen-containing heterocycle that is attached to the H-atom depicted for the compound of formula XXXIV *via* a nitrogen atom in the heterocycle;

(viii) for compounds of formula A1 in which A represents a phenyl group optionally substituted by one or more R^{4a} groups, reaction of a compound of formula XXXV,



XXXV

wherein X^7 represents a suitable leaving group, L^2 represents a direct bond, and B and R^{4a} are as defined in Claim 1, with a compound of formula XXXVI,



XXXVI

wherein R^1 is H; and

(ix) for compounds of formula A1 in which one of R^{4a} to R^{4d} represents -OH, reaction of a compound of formula A1 in which one of R^{4a} to R^{4d} represents $-OR^{4y}$, wherein R^{4y} represents a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-6} cycloalkyl, which groups are optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl and aryl, with a dealkylating agent.

Claims

1. A compound of formula Iyd,



Iyd

wherein:

B represents a Cy^{BB} or Het^{BB};

Cy^{BB} represents phenyl optionally substituted by one or more R^{4c} substituents;

Het^{BB} represents a 6-membered aromatic heterocyclic group which contains one or more N atoms, and which Het^{BB} group is optionally substituted by one or more R^{4d} substituents;

R^{4b}, $R^{4b'}$, R^{4c} and R^{4d} represent, independently at each occurrence,

(a) halo,

(b) CN,

(c) C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{5a}, $S(O)_qR^{5b}$, $S(O)_2N(R^{5c})(R^{5d})$, $N(R^{5e})S(O)_2R^{5f}$, $N(R^{5g})(R^{5h})$, B^1-$C(G^1)$-B^2-R^{5i}, aryl and Het^1,

(d) Cy^3, which Cy^3 group is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{6a}, $S(O)_qR^{6b}$, $S(O)_2N(R^{6c})(R^{6d})$, $N(R^{6e})S(O)_2R^{6f}$, $N(R^{6g})(R^{6h})$, B^3-$C(G^1)$-B^4-R^{6i}, aryl and Het^2,

(e) Het^a, which Het^a group is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{7a}, $S(O)_qR^{7b}$, $S(O)_2N(R^{7c})(R^{7d})$, $N(R^{7e})S(O)_2R^{7f}$, $N(R^{7g})(R^{7h})$, B^5-$C(G^1)$-B^6-R^{7i}, aryl and Het^3,

(f) OR^8,

(g) $S(O)_rR^{9a}$,

(h) $S(O)_2N(R^{9b})(R^{9c})$,

(i) $N(R^{9d})S(O)_2R^{9e}$,

(j) $N(R^{9f})(R^{9g})$,

(k) B^7-$C(G^1)$-B^8-R^{9h},

(l) =O,

(m) =S,

rr2 represents 0 to 2;

ss and tt independently represent, at each occurrence 0 or 1, provided that ss and tt do not both represent 0;

L^1 and L^2 both represent direct bonds;

G^1 represents, independently at each occurrence, O, S or NR^{5j};

R^8 represents, independently at each occurrence,

H,

Cy^3, Het^a, $aryl^a$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-8} cycloalkyl, which latter seven groups are optionally substituted by one or more substituents selected from halo, -CN, C_{3-6} cycloalkyl, aryl, Het^4, $-C(O)OR^{10}$, $-C(O)R^{11}$, $-C(O)N(R^{N1})(R^{N2})$, $S(O)_rR^{9aa}$, $S(O)_2N(R^{9ba})(R^{9ca})$, $N(R^{9da})S(O)_2R^{9ea}$ and $N(R^{9fa})(R^{9ga})$;

Cy^3 represents, independently at each occurrence, a 3- to 6-membered aromatic, fully saturated or partially unsaturated carbocyclic ring;

Het^a represents, independently at each occurrence, a 3- to 6-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N;

R^{10} and R^{11} independently represent

(a) H,

(b) C_{1-6} alkyl optionally substituted by one or more substituents selected from halo, aryl, $-N(R^{N3})(R^{N4})$ and $-OR^a$,

(c) aryl or

(d) C_{3-7} cycloalkyl (which group is optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

B^1 to B^8 independently represent, at each occurrence, a direct bond, O, S or $N(R^{N3})$;

each $aryl^a$ independently represents a C_{6-14} carbocyclic aromatic group, which group may comprise one, two or three rings;

each aryl independently represents a C_{6-14} carbocyclic aromatic group, which group may comprise one, two or three rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N4})(R^{N5})$ and $-OR^a$, and

$-OR^a$;

Het^1 to Het^4 independently represent 4- to 14-membered heterocyclic groups containing one or more heteroatoms selected from O, S and N, which heterocyclic groups may comprise one, two or three rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N6})(R^{N7})$ and $-OR^a$, and

$-OR^a$;

R^{N1} to R^{N7} independently represent

H,

C_{1-6} alkyl or C_{3-6} cycloalkyl, which latter two groups are optionally substituted by one or more substituents selected from halo and $-OR^a$;

R^a represents, independently at each occurrence,

(a) H;

(b) C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{3-12} cycloalkyl, C_{4-12} cycloalkenyl, which latter five groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl (which latter four groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{12a}, $S(O)_qR^{12b}$, $S(O)_2N(R^{12c})(R^{12d})$, $N(R^{12e})S(O)_2R^{12f}$, $N(R^{12g})(R^{12h})$, B^9-$C(G^2)$-B^{10}-R^{12i}, aryl[1] and Het^b, and which C_{3-12} cycloalkyl or C_{4-12} cycloalkenyl groups may additionally be substituted by =O,

(c) $S(O)_rR^{13a}$,

(d) $S(O)_2N(R^{13b})(R^{13c})$ or

(e) $C(O)$-B^{11}-R^{13d};

R^{5a} to R^{5j}, R^{6a} to R^{6i}, R^{7a} to R^{7i}, R^{9a} to R^{9h}, R^{9aa} to R^{9ga}, R^{12a} to R^{12i} and R^{13a} to R^{13d} independently represent, at each occurrence,

(a) H,

(b) C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy), OR^{5aa}, $S(O)_qR^{5ab}$, $S(O)_2N(R^{5ac})(R^{5ad})$, $N(R^{5ae})S(O)_2R^{5af}$, $N(R^{5ag})(R^{5ah})$, B^{12}-$C(G^2)$-B^{13}-R^{5ai}, aryl[1] and Het^c;

(c) C_{3-10} cycloalkyl, or C_{4-10} cycloalkenyl (which latter two groups are optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-6} alkyl and C_{1-6} alkoxy),

(d) Het^d;

G^2 represents, independently at each occurence, O, S, or NR^{5aj};

R^{5aa} to R^{5aj} independently represent at each occurrence,

(a) H,

(b) C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy),

(c) C_{3-6} cycloalkyl, or C_{4-6} cycloalkenyl (which latter two groups are optionally substituted by one or more substituents selected from halo, OH, =O, C_{1-4} alkyl and C_{1-4} alkoxy),

(d) Het^e,

or R^{5ag} and R^{5ah} may represent, together with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which may additionally contain one or more heteroatoms selected from O, S and N, which heterocyclic ring is optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

B^9 to B^{13} independently represent a direct bond, O, S or $N(R^{N8})$;

$aryl^1$ represents, independently at each occurrence, a C_{6-10} carbocyclic aromatic group, which group may comprise one or two rings and may be substituted by one or more substituents selected from

halo,

C_{1-6} alkyl, which latter group is optionally substituted by one or more substituents selected from halo, $-N(R^{N10})(R^{N11})$ and C_{1-6} alkoxy (which latter substituent is optionally substituted by one or more halo atoms), and

C_{1-6} alkoxy (which latter substituent is optionally substituted by one or more halo atoms);

R^{N8}, R^{N10} and R^{N11} independently represent

H,

C_{1-6} alkyl or C_{3-6} cycloalkyl, which latter two groups are optionally substituted by one or more halo atoms;

Het^b represents a 5- or 6-membered that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may be substituted by one or more substituents selected from halo, =O and C_{1-6} alkyl;

Het^c to Het^e independently represent, a 3- to 6-membered heterocyclic ring that may be aromatic, fully saturated or partially unsaturated and which contains one or more heteroatoms selected from O, S and N, which Het^c to Het^e groups are optionally substituted by one or more substituents selected from halo, nitro, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl (which latter three groups are optionally substituted by one or more substituents selected from OH, =O, halo, C_{1-4} alkyl and C_{1-4} alkoxy);

q and r independently represent at each occurrence 0, 1 or 2; and

unless otherwise specified alkyl, alkenyl, alkynyl, cycloalkyl and the alkyl part of alkoxy groups may be substituted by one or more halo atoms;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound as claimed in Claim 1, wherein R^{4b} and $R^{4b'}$ represent, independently at each occurrence

(a) halo,

(b) CN,

(c) C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, which latter three groups are optionally substituted by one or more substituents selected from halo, nitro, CN, OR^{5a}, $S(O)_qR^{5b}$, $S(O)_2N(R^{5c})(R^{5d})$, $N(R^{5e})S(O)_2R^{5f}$, $N(R^{5g})(R^{5h})$, B^1-$C(G^1)$-B^2-R^{5i} and Het^1 (e.g. one or more substituents selected from nitro, CN, OR^{5a}, $S(O)_qR^{5b}$, $S(O)_2N(R^{5c})(R^{5d})$, $N(R^{5e})S(O)_2R^{5f}$, $N(R^{5g})(R^{5h})$, B^1-$C(G^1)$-B^2-R^{5i} and Het^1),

(d) Cy^3, which Cy^3 group is optionally substituted by one or more substituents selected from nitro, CN, OR^{6a}, $S(O)_qR^{6b}$, $S(O)_2N(R^{6c})(R^{6d})$, $N(R^{6e})S(O)_2R^{6f}$, $N(R^{6g})(R^{6h})$, B^3-$C(G^1)$-B^4-R^{6i} and Het^2,

(e) Het^a, which Het^a group is optionally substituted by one or more substituents selected from halo, nitro, CN, OR^{7a}, $S(O)_qR^{7b}$, $S(O)_2N(R^{7c})(R^{7d})$, $N(R^{7e})S(O)_2R^{7f}$, $N(R^{7g})(R^{7h})$, B^5-$C(G^1)$-B^6-R^{7i} and Het^3,

(f) OR^8,

(g) $S(O)_rR^{9a}$,

(h) $S(O)_2N(R^{9b})(R^{9c})$,

(i) $N(R^{9d})S(O)_2R^{9e}$,

(j) $N(R^{9f})(R^{9g})$ or

(k) B^7-$C(G^1)$-B^8-R^{9h},

wherein R^{5a} to R^{5i}, R^{6a} to R^{6i}, R^{7a} to R^{7i}, R^8, R^{9a} to R^{9h}, Cy^3, Het^1 to Het^3, Het^a, B^1 to B^8, G^1, q and r are as defined in Claim 1.

3. A compound as claimed in Claim 1 or Claim 2, wherein:

$R^{4b'}$ and R^{4b} represent, independently at each occurrence, cyclopropyl, iodo, bromo, chloro, fluoro, ethyl, methyl, d_3-methyl, iso-propyl, -C≡CH, phenyl, CF_3, CHF_2, CH_2F, CH_2CF_3, CF_2CF_3, CN, =O, OH, $OCH(CH_3)_2$, OCH_3, OCH_2CH_3, OCH_2F, $OCHF_2$, OCH_2CF_3, OCF_3, $(CH_2)_3OH$, CH_2OH or CH_2OCH_3, $CH(CH_3)OH$, $C(CH_3)_3OH$, CH_2CH_2OH,

NH_2, $N(CH_3)_2$, $N(H)CH_2CH_3$, $N(H)C(O)CH_3$, $C(O)CH_3$, $C(O)N(CH_3)_2$, $S(O)_2CH_3$, $S(O)CH_3$, SCH_3, $S(O)_2CF_3$, azetidine, morpholine or dioxolane.

4. A compound as claimed in any one of Claims 1 to 3, wherein:

(A) (1) R^{4b} represents, independently at each occurrence, OH, $OCH(CH_3)_2$, OCH_3, OCH_2CH_3, OCH_2F, $OCHF_2$, OCH_2CH_3, OCH_2CF_3, OCH_3, OCF_3, $(CH_2)_3OH$, CH_2OH or CH_2OCH_3, NH_2, $NHCH(CH_3)_2$, $NHCH_3$, $NHCH_2CH_3$, $NHCH_2CH_3$, $NH(CH(CH_3)_2)_2$, $NH(CH_3)_2$, $NH(CH_2CH_3)_2$ or $NH(CH_2CH_3)_2$);

(2) the sum of ss and tt is 1; and

(3) rr2 is 0; or

(B) (1) R^{4b} represents, independently at each occurrence, CH_2F or, particularly, cyclopropyl, chloro, fluoro, ethyl, methyl, CF_3, CHF_2, CH_2CF_3, CF_2CF_3, OH, $OCH(CH_3)_2$, OCH_3, OCH_2CH_3, OCH_2F, $OCHF_2$, OCH_2CH_3, OCH_2CF_3, OCH_3, OCF_3, $(CH_2)_3OH$, CH_2OH or CH_2OCH_3;

(2) ss and tt are both 1; and

(3) rr2 is 0.

5. A compound as claimed in any one of Claims 1 to 4, wherein the compound of formula Iyd is selected from the list comprising:

(lxiii) 6-(2-chloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxvi) 6-(2-chloro-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxix) 6-(2-methoxy-6-(trifluoromethyl)pyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(lxxxvi) 6-(2-methoxypyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xcvi) 6-(2,6-dimethoxypyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xcvii) 6-(2,6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(xcviii) 5-phenyl-6-(2-(trifluoromethyl)pyridin-4-yl)-1,2,4-triazin-3-amine;

(xcix) 6-(2-cyclopropylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cii) 6-(2,6-dichloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cix) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(cxiii) 6-(2-chloropyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cxiv) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cxvii) 5-(4-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(cxviii) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-chlorophenyl)-1,2,4-triazin-3-amine;

(cxxi) 5-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxii) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3-chlorophenyl)-1,2,4-triazin-3-amine;

(cxxiv) 4-(3-amino-6-(2-chloro-6-methylpyridin-4-yl)-1,2,4-triazin-5-yl)benzonitrile;

(cxxvi) 5-(3-chloro-5-fluorophenyl)-6-(2-chloro-6-methylpyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxix) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;

(cxxxii) 5-(3-chloro-4-fluorophenyl)-6-(2-chloro-6-methylpyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxxiii) 5-(3-chloro-4-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(cxxxvi) 6-(2-chloro-6-methylpyridin-4-yl)-5-(3,4-difluorophenyl)-1,2,4-triazin-3-amine;

(cxxxvii) 6-(2-chloropyridin-4-yl)-5-(3,4-difluorophenyl)-1,2,4-triazin-3-amine;

(cxl) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-3-amine;

(cxli) 6-(2,6-dimethylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(clvii) 4-(3-amino-6-(2-chloropyridin-4-yl)-1,2,4-triazin-5-yl)benzonitrile;

(clix) 6-(2-chloropyridin-4-yl)-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-3-amine;

(ccviii) 5-(3-chloro-5-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(ccix) 6-(2-chloropyridin-4-yl)-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;

(ccxi) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-(difluoromethoxy)phenyl)-1,2,4-triazin-3-amine;

(ccxii) 6-(2-chloropyridin-4-yl)-5-(4-(difluoromethoxy)phenyl)-1,2,4-triazin-3-amine;

(ccxvii) 5-(3-chloro-5-fluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxviii) 5-(3,5-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxix) 5-(3,4-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxx) 5-(3-chloro-4-fluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxi) 5-(4-(difluoromethoxy)phenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxii) 6-(2,6-dimethylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(ccxxiii) 5-(4-chlorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxiv) 4-(3-amino-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-5-yl)benzonitrile;

(ccxxv) 5-(3-chlorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxxvi) 6-(2,6-dimethylpyridin-4-yl)-5-(4-(methoxymethyl)phenyl)-1,2,4-triazin-3-amine;

(ccxxxix) 5-(3-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;

(ccxli) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(3,4-difluorophenyl)-1,2,4-triazin-3-amine;

(ccxlii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(3,5-difluorophenyl)-1,2,4-triazin-3-amine;

(ccxliii) 6-[2-(ethylamino)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccxliv) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(ccxlv) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(ccxlvi) 6-{2-[ethyl(methyl)amino]-6-methylpyridin-4-yl}-5-phenyl-1,2,4-triazin-3-amine;

(ccxlvii) 6-[2-(dimethylamino)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccxlviii) 1-[6-(2,6-d6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxlix) 6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccl) 5-(4-fluorophenyl)-6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(ccli) 6-(2,6-dimethylpyridin-4-yl)-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(cclii) 6-(2-chloro-6-methylpyridin-4-yl)-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(ccliii) 6-(2,6-dimethylpyridin-4-yl)-5-(4-methoxyphenyl)-1,2,4-triazin-3-amine;

(ccliv) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-methoxyphenyl)-1,2,4-triazin-3-amine;

(cclv) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclvi) 6-[2-chloro-6-(difluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclvii) 6-[2-chloro-6-(fluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclviii) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cclix) 6-[2,6-bis(fluoromethyl)pyridine-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclx) 6-[2-(fluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxi) 6-(2-chloro-6-methylpyridin-4-yl)-5-(2,5-difluorophenyl)-1,2,4-triazin-3-amine;

(cclxii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxiii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2,5-difluorophenyl)-1,2,4-triazin-3-amine;

(cclxiv) 6-[2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxv) 6-[2-ethyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxvi) 6-(2-cyclopropyl-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cclxvii) 5-(2-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxviii) 5-(3-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxix) 5-(4-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxx) 5-(2,5-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxxi) 5-(3,4-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxxii) 5-(3,5-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;

(cclxxiii) 6-[2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxxiv) 6-[2-methyl-6-(morpholin-4-yl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxv) 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-ethylphenyl)-1,2,4-triazin-3-amine;

(cclxxvi) 5-(2,5-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;

(cclxxvii) 6-(2,6-dimethylpyridin-4-yl)-5-(4-methylphenyl)-1,2,4-triazin-3-amine;

(cclxxviii) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxxix) 6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;

(cclxxxii) 6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxiii) 6-[2,6-bis(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxv) 6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxvii) 6-[2-(dimethylamino)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxviii) 6-(2-bromo-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cclxxxix) 6-(2,6-dimethyl-1-oxidopyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(ccxc) 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-6-methylpyridine-2-carbonitrile;

(ccxcv) 6-[2-bromo-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccc) 6-(2-methyl-6-d3-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

(cccii) 6-[2-(azetidin-1-yl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;

(ccciii) 6-[2-(azetidin-1-yl)-6-methylpyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; and

(ccciv) 6-[2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine.

6. A compound as claimed in any one of Claims 1 to 5, wherein the compound of formula Iyd is selected from:

6-(2-chloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

6-(2-chloro-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

6-(2-methoxypyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

6-(2,6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;

5-phenyl-6-(2-(trifluoromethyl)pyridin-4-yl)-1,2,4-triazin-3-amine;

6-(2-cyclopropylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
6-(2,6-dichloropyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
6-(2-chloro-6-methylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;
5-(4-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
5-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
5-(3-chloro-4-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
6-(2,6-dimethylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
5-(3,5-difluorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;
6-(2,6-dimethylpyridin-4-yl)-5-(3-fluorophenyl)-1,2,4-triazin-3-amine;
5-(4-chlorophenyl)-6-(2,6-dimethylpyridin-4-yl)-1,2,4-triazin-3-amine;
5-(3-fluorophenyl)-6-(2-chloropyridin-4-yl)-1,2,4-triazin-3-amine;
6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-(2-chloro-6-methylpyridin-4-yl)-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;
6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2-fluorophenyl)-1,2,4-triazin-3-amine;
6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-(2,5-difluorophenyl)-1,2,4-triazin-3-amine;
6-(2-cyclopropyl-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine;
5-(2-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
5-(3-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
5-(4-fluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
5-(3,5-difluorophenyl)-6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
6-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-bromo-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-(azetidin-1-yl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;
5-(4-fluorophenyl)-6-[2-d3-methyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazin-3-amine;
6-[2-(difluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-chloro-6-(difluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-chloro-6-(fluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-(fluoromethyl)-6-methylpyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine;
6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine; and
6-(2-bromo-6-methylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine .

7. A compound selected from the group comprising:
6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine and
6-[2-methyl-6-(trifluoromethyl)pyridin-4-yl]-5-phenyl-1,2,4-triazin-3-amine,
or a pharmaceutically acceptable salt or solvate thereof.

8. A compound as claimed in any one of Claims 1 to 7, wherein:
B represents a Cy^{BB} or Het^{BB} group, which group is either unsubstituted or is substituted by one or more substituents selected from fluoro, CN, OR^8 or C_{1-6} alkyl optionally substituted by one or more substituents selected from halo and OR^{5a}, wherein R^{5a} and R^8 are as defined in Claim 1
optionally wherein B represents a Cy^{BB} or Het^{BB} group, which group is either unsubstituted or is substituted by fluoro at the 4-position relative to the point of attachment to the triazine ring.

9. A compound of formula Iyd as defined in any one of Claims 1 to 7 for use in the treatment of a condition or disorder ameliorated by the inhibition of the A_1 receptor or the A_{2a} receptor wherein the condition or disorder is selected from: heart failure; kidney failure; oedema; cancer; diabetes; diarrhea; macular degeneration; depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour.

10. The use of a compound of formula Iyd as defined in any one of Claims 1 to 7 for the manufacture of a medicament for the treatment of a condition or disorder ameliorated by the inhibition of the A_1 receptor or the A_{2a} receptorwherein the condition or disorder is selected from: heart failure; kidney failure; oedema; cancer; diabetes; diarrhea; macular degeneration; depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour.

11. Use as claimed in Claim 10, or compound for use as claimed in Claim 9, wherein the condition or disorder is ameliorated by the inhibition of the A_{2a} receptor and is selected from depression; cognitive function diseases; a neurodegenerative disease; an attention related disorder; extra pyramidal syndrome; a disorder of abnormal movement; cirrhosis; liver fibrosis; fatty liver; dermal fibrosis; a sleep disorder; stroke; brain injury or neuroinflammation; and addictive behaviour.

12. Use as claimed in Claim 10 or Claim 11, or compound for use as claimed in Claim 9 or Claim 11, wherein the condition or disorder is migraine.

13. Use as claimed in Claim 10 or Claim 11, or compound for use as claimed in Claim 9 or Claim 11, wherein the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease or amyotrophic lateral sclerosis.

14. Use, or compound for use as claimed in Claim 13, wherein the condition or disorder ameliorated by the inhibition of the A_{2a} receptor is Parkinson's disease.

15. Use as claimed in Claim 10 or Claim 11, or compound for use as claimed in Claim 9 or Claim 11, wherein the condition or disorder ameliorated by the inhibition of the A_{2a} receptor is addictive behaviour or ADHD.

16. Compound for use as claimed in Claim 9 or Claim 11, or use as claimed in Claim 10 or Claim 11, wherein the condition or disorder ameliorated by the inhibition of the A_1 receptor is mitigation of kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

17. A compound of formula Iyd as defined in any one of Claims 1 to 7 for use in mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

18. The use of compound of formula Iyd as defined in any one of Claims 1 to 7 for the manufacture of a medicament for mitigating kidney damage caused by acute renal failure, oedema, heart failure, chronic renal disease and/or cirrhosis.

19. A compound of formula Iyd as claimed in any one of Claims 1 to 7 for use in medicine.

20. A pharmaceutical formulation including a compound of formula Iyd as defined in any one of Claims 1 to 7 in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. A process for the preparation of a compound of formula Iyd as defined in any one of Claims 1 to 7, which process comprises:

(i)(a) reaction of a compound of formula III,



III

wherein L^{x1a} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, wherein each R^{x1} mentioned herein independently represents a C_{1-6} alkyl group, or, in the case of $-B(OR^{x1})_2$, the two R^{x1} groups may be linked together to form a 4- to 6-membered cyclic group, L^2 represents a direct bond, R^1 represents H, and B is as defined in Claim 1, with a compound of formula IV,

$$A—X^{1a} \qquad IV$$

wherein X^{1a} represents a suitable leaving group, and A represents the requisite substituted pyridine-4-yl group as defined in Claim 1;

(b) reaction of a compound of formula V,



V

wherein X^{1b} represents a suitable leaving group, L^2 represents a direct bond, R^1 represents H, and B is as defined in Claim 1, with a compound of formula VI,

$$A—L^{x1b} \qquad VI$$

wherein L^{x1b} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, wherein each R^{x1} is as defined above, and A represents the requisite substituted pyridine-4-yl group as defined in Claim 1;

(ii)(a) reaction of a compound of formula XV,



XV

wherein L^{x3a} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, in which each R^{x1} is as defined above, L^1 represents a direct bond, R^1 represents H, and A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, with a compound of formula XVI,

$$B—X^{3a} \qquad XVI$$

wherein X^{3a} represents a suitable leaving group and B is as defined in Claim 1;

(b) reaction of a compound of formula XVII,



XVII

wherein X^{3b} represents a suitable leaving group, L^1 represents a direct bond, R^1 represents H, and A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, with a compound of formula XVIII,

$$B—L^{x3b} \qquad \text{XVIII}$$

wherein L^{x3b} represents a metal halide, $-Sn(R^{x1})_3$, an alkyl-cyclotriboroxane derivative, $-B(OH)_2$, $-B(OR^{x1})_2$, or an organosilane, in which each R^{x1} is as defined above, and B is as defined in Claim 1;

(iii) reaction of a compound of formula XXVIII,



XXVIII

wherein X^6 represents a suitable leaving group such, L^1 and L^2 represent direct bonds, A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, and B is as defined in Claim 1, with a compound of formula XXIX,

$$R^1NH_2 \qquad \text{XXIX}$$

wherein R^1 is H;

(iv) reaction of a compound of formula XXX,



XXX

wherein R^{x2} represents a suitable leaving group, L^1 and L^2 represent direct bonds, A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, and B is as defined in Claim 1, or a protected derivative thereof, with a compound of formula XXIX, wherein R^1 is H;

(v) reaction of a compound of formula XXXI,



XXXI

wherein A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, and B is as defined in Claim 1, with a compound of formula XXXII,



XXXII

wherein R^1 is H;

(vi) for compounds of formula Iyd in which A represents a nitrogen-containing Het^{AA} group that is attached *via* a nitrogen atom within the ring system, reaction of a compound of formula VII,



VII

wherein X^{2a} represents a suitable leaving group, L^2 represents a direct bond, R^1 represents H, and B is as defined in Claim 1, with a compound of formula XXXIII,

Het^{A1}—H XXXIII

wherein Het^{A1} takes the same definition as Het^{AA} as defined above, except that Het^{A1} is a nitrogen-containing heterocycle that is attached to the H-atom depicted for the compound of formula XXXIII *via* a nitrogen atom in the heterocycle;

(vii) for compounds of formula Iyd in which B represents a nitrogen-containing Het^{BB} group that is attached *via* a nitrogen atom within the ring system, reaction of a compound of formula XIX,



XIX

wherein X^{4a} represents a suitable leaving group, L^1 represents a direct bond, R^1 represents H, and A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, with a compound of formula XXXIV,

Het^{B1}—H XXXIV

wherein Het^{B1} takes the same definition as Het^{BB} as defined above, except that Het^{B1} is a nitrogen-containing heterocycle that is attached to the H-atom depicted for the compound of formula XXXIV *via* a nitrogen atom in the heterocycle; and

(ix) for compounds of formula Iyd in which one of $R^{4b'}$ R^{4b}, R^{4c} and R^{4d} represents -OH, reaction of a compound of formula Iyd in which one of R4b', R^{4b}, R^{4c} and R^{4d} represents -OR^{4y}, wherein R^{4y} represents a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-6} cycloalkyl, which groups are optionally substituted by one or more substituents selected from halo, C_{1-4} alkyl and aryl, with a dealkylating agent.